Valneva (NASDAQ:VALN) Posts Quarterly Earnings Results, Misses Estimates By $0.21 EPS

Posted by on May 14th, 2026

Valneva (NASDAQ:VALN – Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.21), Zacks reports. Valneva had a negative return on equity of 76.81% and a negative net margin of 67.64%.The company had revenue of $36.16 million for the quarter, compared to the consensus estimate of $47.15 million.

Here are the key takeaways from Valneva’s conference call:

  • Valneva said the Lyme vaccine missed one pre-specified statistical criterion, although the second criterion was met and Pfizer still plans regulatory submissions. The company emphasized the readout was limited by fewer-than-expected Lyme cases, which widened confidence intervals.
  • The company reported more than EUR 100 million in cash at quarter-end excluding recent financing proceeds, and it launched a restructuring aimed at cutting operating expenses by 25%–35% versus last year. Valneva also expects a 10%–15% workforce reduction.
  • Q1 product sales fell to EUR 30.5 million from EUR 48.6 million a year ago, driven by lower IXIARO, DUKORAL, and IXCHIQ sales as well as a sharp drop in third-party product revenue. The company also cut full-year 2026 guidance to EUR 135 million–EUR 150 million in product sales and EUR 145 million–EUR 160 million in total revenues.
  • Management said Q1 gross margin was hurt by manufacturing transfer costs, idle capacity, batch write-offs, and onerous contract charges, particularly for IXCHIQ. They expect margin to normalize later in the year, but also noted idle capacity costs remain elevated after the move to the Almeida facility.
  • Valneva highlighted continued progress across its pipeline, including IXCHIQ rollout in Brazil, where more than 30,000 people have already been vaccinated, and upcoming Shigella data readouts expected over the summer. Management also reiterated that Pfizer is preparing regulatory meetings for Lyme and will present the full dataset at a future conference.

Valneva Stock Up 0.7%

Shares of Valneva stock traded up $0.04 on Thursday, hitting $5.91. The company had a trading volume of 4,160 shares, compared to its average volume of 64,893. The stock has a market capitalization of $508.82 million, a price-to-earnings ratio of -3.71 and a beta of 1.72. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.85 and a current ratio of 2.38. Valneva has a 1 year low of $5.06 and a 1 year high of $12.25. The stock has a 50 day moving average of $7.28 and a 200-day moving average of $8.64.

Analyst Ratings Changes

Several research analysts have issued reports on the company. The Goldman Sachs Group lowered Valneva from a “neutral” rating to a “sell” rating and set a $4.90 price target on the stock. in a report on Wednesday, April 22nd. Wall Street Zen lowered Valneva to a “strong sell” rating in a research report on Saturday, April 25th. Finally, Guggenheim set a $11.00 target price on Valneva in a report on Thursday, April 16th. Three analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Valneva has an average rating of “Hold” and a consensus target price of $11.98.

Read Our Latest Research Report on Valneva

Institutional Investors Weigh In On Valneva

A number of institutional investors and hedge funds have recently bought and sold shares of VALN. Marex Group plc bought a new stake in shares of Valneva in the 2nd quarter worth $64,000. XTX Topco Ltd bought a new position in shares of Valneva during the fourth quarter valued at about $94,000. Finally, JPMorgan Chase & Co. purchased a new position in Valneva during the third quarter worth about $124,000. 11.39% of the stock is owned by hedge funds and other institutional investors.

Valneva Company Profile

(Get Free Report)

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.

Read More

Earnings History for Valneva (NASDAQ:VALN)

Receive News & Ratings for Valneva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valneva and related companies with MarketBeat.com's FREE daily email newsletter.